IS5159A - Inverse hydroxamate derivatives that metal protease inhibits - Google Patents
Inverse hydroxamate derivatives that metal protease inhibitsInfo
- Publication number
- IS5159A IS5159A IS5159A IS5159A IS5159A IS 5159 A IS5159 A IS 5159A IS 5159 A IS5159 A IS 5159A IS 5159 A IS5159 A IS 5159A IS 5159 A IS5159 A IS 5159A
- Authority
- IS
- Iceland
- Prior art keywords
- inverse
- metal protease
- hydroxamate derivatives
- protease inhibits
- inhibits
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Detergent Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3911297P | 1997-02-26 | 1997-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
IS5159A true IS5159A (en) | 1999-08-20 |
Family
ID=21903750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS5159A IS5159A (en) | 1997-02-26 | 1999-08-20 | Inverse hydroxamate derivatives that metal protease inhibits |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1019386A1 (en) |
JP (1) | JP2001513767A (en) |
KR (1) | KR20000075681A (en) |
AP (1) | AP9901631A0 (en) |
AR (1) | AR013070A1 (en) |
AU (1) | AU6822398A (en) |
BR (1) | BR9807763A (en) |
CA (1) | CA2281664A1 (en) |
HR (1) | HRP980096A2 (en) |
IS (1) | IS5159A (en) |
NO (1) | NO994103L (en) |
PE (1) | PE59199A1 (en) |
PL (1) | PL335378A1 (en) |
TR (1) | TR199902063T2 (en) |
WO (1) | WO1998038179A1 (en) |
ZA (1) | ZA981532B (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6235786B1 (en) | 1997-08-06 | 2001-05-22 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
US6294573B1 (en) | 1997-08-06 | 2001-09-25 | Abbott Laboratories | Reverse hydroxamate inhibitors of matrix metalloproteinases |
JP2002502815A (en) | 1998-02-07 | 2002-01-29 | ブリティッシュ バイオテック ファーマシューティカルズ リミテッド | Antibacterial agent |
WO2000012466A1 (en) * | 1998-08-26 | 2000-03-09 | Glaxo Group Limited | Formamide compounds as therapeutic agents |
EP1121118A4 (en) * | 1998-08-26 | 2002-09-11 | Glaxo Group Ltd | Formamides as therapeutic agents |
GB9818621D0 (en) * | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Formamide compounds as therapeutic agents |
US6288261B1 (en) | 1998-12-18 | 2001-09-11 | Abbott Laboratories | Inhibitors of matrix metalloproteinases |
US6329550B1 (en) | 1998-12-31 | 2001-12-11 | Aventis Pharmaceuticals Inc. | Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase |
GB9918869D0 (en) * | 1999-08-10 | 1999-10-13 | British Biotech Pharm | Antibacterial agents |
JP2003081838A (en) * | 2001-09-11 | 2003-03-19 | Rohto Pharmaceut Co Ltd | Glucosamine preparation |
AU2003208525B9 (en) | 2002-02-04 | 2009-08-27 | Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda | Amend the invention title to read Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof |
EP1622617A2 (en) * | 2003-02-11 | 2006-02-08 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions based on anticholinergics and tace-inhibitors |
JP2009533318A (en) * | 2006-02-09 | 2009-09-17 | ザ バーナム インスティテュート | Inhibitors of membrane type 1 matrix metalloproteinases for the treatment of insulin-dependent diabetes |
AU2008350907A1 (en) | 2007-12-11 | 2009-08-27 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
PT2105164E (en) | 2008-03-25 | 2011-03-24 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
MX2011010810A (en) | 2009-04-14 | 2012-01-12 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use. |
WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
PT2699242T (en) | 2011-04-19 | 2018-01-22 | Alfama Inc | Carbon monoxide releasing molecules and uses thereof |
WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
ES2628634T3 (en) | 2011-07-21 | 2017-08-03 | Alfama, Inc. | Carbon monoxide-ruthenium releasing molecules and uses thereof |
US20210393632A1 (en) | 2018-10-04 | 2021-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9223904D0 (en) * | 1992-11-13 | 1993-01-06 | British Bio Technology | Inhibition of cytokine production |
US6037472A (en) * | 1993-11-04 | 2000-03-14 | Syntex (U.S.A.) Inc. | Matrix metalloprotease inhibitors |
DK0822186T3 (en) * | 1994-01-20 | 2000-06-26 | British Biotech Pharm | L- tert -leucine-2-pyridylamide |
GB9514867D0 (en) * | 1995-07-20 | 1995-09-20 | British Biotech Pharm | Metalloproteinase inhibitors |
JP2000500761A (en) * | 1995-11-23 | 2000-01-25 | ブリティッシュ バイオテック ファーマシューティカルズ リミテッド | Metalloproteinase inhibitors |
-
1998
- 1998-02-24 CA CA002281664A patent/CA2281664A1/en not_active Abandoned
- 1998-02-24 EP EP98913575A patent/EP1019386A1/en not_active Withdrawn
- 1998-02-24 ZA ZA9801532A patent/ZA981532B/en unknown
- 1998-02-24 TR TR1999/02063T patent/TR199902063T2/en unknown
- 1998-02-24 JP JP53728498A patent/JP2001513767A/en active Pending
- 1998-02-24 BR BR9807763-5A patent/BR9807763A/en not_active Application Discontinuation
- 1998-02-24 PL PL98335378A patent/PL335378A1/en unknown
- 1998-02-24 WO PCT/EP1998/001015 patent/WO1998038179A1/en not_active Application Discontinuation
- 1998-02-24 KR KR1019997007747A patent/KR20000075681A/en not_active Application Discontinuation
- 1998-02-24 HR HR60/039,112A patent/HRP980096A2/en not_active Application Discontinuation
- 1998-02-24 AP APAP/P/1999/001631A patent/AP9901631A0/en unknown
- 1998-02-24 AU AU68223/98A patent/AU6822398A/en not_active Abandoned
- 1998-02-25 PE PE1998000138A patent/PE59199A1/en not_active Application Discontinuation
- 1998-02-25 AR ARP980100842A patent/AR013070A1/en unknown
-
1999
- 1999-08-20 IS IS5159A patent/IS5159A/en unknown
- 1999-08-25 NO NO994103A patent/NO994103L/en unknown
Also Published As
Publication number | Publication date |
---|---|
NO994103L (en) | 1999-10-25 |
KR20000075681A (en) | 2000-12-26 |
ZA981532B (en) | 1999-08-24 |
CA2281664A1 (en) | 1998-09-03 |
EP1019386A1 (en) | 2000-07-19 |
PL335378A1 (en) | 2000-04-25 |
TR199902063T2 (en) | 1999-12-21 |
AP9901631A0 (en) | 1999-09-30 |
AU6822398A (en) | 1998-09-18 |
JP2001513767A (en) | 2001-09-04 |
NO994103D0 (en) | 1999-08-25 |
PE59199A1 (en) | 1999-06-24 |
AR013070A1 (en) | 2000-12-13 |
BR9807763A (en) | 2000-02-22 |
WO1998038179A1 (en) | 1998-09-03 |
HRP980096A2 (en) | 1998-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS5159A (en) | Inverse hydroxamate derivatives that metal protease inhibits | |
IS6164A (en) | Metal protease inhibits | |
NO990760D0 (en) | 1,4-heterocyclic metal protease inhibitors | |
DE59711960D1 (en) | METAL GASKET | |
IS5125A (en) | Sulfamide metal protease inhibits | |
ATE244797T1 (en) | METAL PILLOW WALL | |
NO20012980D0 (en) | protease inhibitors | |
DE69916031D1 (en) | ASORBABLE MICROPARTICLES | |
DE69915742D1 (en) | steel alloys | |
NO20005196D0 (en) | Substituted pyrrolidine hydroxamate metal protease inhibitors | |
DE69812454D1 (en) | metal seal | |
ID27574A (en) | ENZYMER INHIBITORS | |
EP1093367A4 (en) | Protease inhibitors | |
IS5412A (en) | Isoquinoline that urokinase inhibits | |
IS5342A (en) | Branched alkoxy-substituted 2-aminopyridine which NOS inhibits | |
DE59912684D1 (en) | FILM-DRIVEN AGENTS | |
EP1067894A4 (en) | Protease inhibitors | |
IS5531A (en) | Lathe metal protease slows | |
EP1079821A4 (en) | Protease inhibitors | |
EP1086083A4 (en) | Protease inhibitors | |
EP1140897A4 (en) | Protease inhibitors | |
DE29803676U1 (en) | Metal conveyor | |
IS5789A (en) | Isoquinoline that urokinase inhibits | |
DE59800483D1 (en) | Rust block | |
GB9817129D0 (en) | Galvanised metal |